Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry

Lille University20 enrolled

Overview

This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.

This is a non-interventional, monocentric, retrospective cohort study aimed at developing a spatial proteomics analysis method for small tumor samples (FFPE) to precisely characterize proteins at the tissue level in rhabdomyosarcoma (RMS). Using mass spectrometry, the study will identify molecular signatures associated with different tumor regions, histological subtypes, patient survival, and treatment resistance. The goal is to identify potential protein biomarkers and therapeutic targets. Data from clinical samples will be analyzed to find biomarkers correlated with survival and resistance to treatment. No patient intervention is required, as the study uses pre-existing biological samples and clinical data.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rhabdomyosarcoma

Interventions

None AHTOTHER

This study does not involve any interventions. It analyzes pre-existing biological samples (FFPE tumor tissue) and clinical data from patients with rhabdomyosarcoma.

Eligibility

Sex: ALLMin age: 0 YearsMax age: 25 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 0 and 25 years at the time of initial diagnosis * Diagnosis of rhabdomyosarcoma confirmed histologically * Care at the Oscar Lambret Center between January 2005 and November 2024 * No objection to the re-use of data and biological samples collected as part of care for research activities. Exclusion Criteria: * Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret; * Patient under guardianship or trusteeship.

Locations (1)

Oscar Lambret Center

Lille, Nord, France

RECRUITING

Outcomes

Primary Outcomes

Spatial Proteomic Profiling of Tumor Samples

Evaluate the ability to obtain distinct proteomic profiles from at least 75% of tumor samples analyzed, with a minimum of two distinct profiles identified per sample.

Time frame: 12 months (study duration)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.